Aurobindo Pharma acquires 80 percent stake in A1 Biochem Labs for USD 17 million

Listed Co AcquisitionStrategic Transactions View source PDF

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+1.7%1-day move

₹1525.80

prior close

₹1512.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+1.2+1.1+1.4+1.4+1.7—————————

Up moveDown movePending

AI summary

Aurobindo Pharma subsidiary Apitoria Pharma will acquire 80 percent stake in A1 Biochem Labs (India) and A1 Biochem Labs LLC, USA at USD 17 million enterprise value, with USD 13.6 million for the 80 percent. A1 Biochem is a CRO with FY26 turnover of INR 1,024 million and EBITDA of INR 465 million. Expected to close in 90 to 120 days, creating an integrated CRDMO platform to complement Apitoria's API manufacturing. All cash, not a related party deal.

Likely market impact

Strengthens API lifecycle with CRDMO capability. Modest size at USD 17 million; adds a profitable, EBITDA-positive CRO to the group.